EMA Recommends Remdesivir for Treatment of COVID-19 Under Compassionate-Use Rules

The European Union's health regulator on Friday took an unusual step and increased access to an experimental drug that might be effective against SARS-CoV-2, the coronavirus that causes COVID-19. Gilead Sciences' (NASDAQ: GILD) antiviral treatment remdesivir is now indicated for the treatment of adults unable to breathe due to COVID-19 as part of a compassionate-use program, said the European Medicines Agency.